Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?
Yamada D, Kobayashi S, Takahashi H, Iwagami Y, Akita H, Asukai K, Shimizu J, Yamada T, Tanemura M, Yokoyama S, Tsujie M, Asaoka T, Takeda Y, Morimoto O, Tomokuni A, Doki Y, Eguchi H. Yamada D, et al. Among authors: asaoka t. Ann Surg Oncol. 2024 May 9. doi: 10.1245/s10434-024-15244-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38722422 No abstract available.
ASO Author Reflections: A Novel Mechanism of Anticancer Effect of Skeletal Muscle-Derived Irisin in Pancreatic Ductal Adenocarcinoma.
Sugimoto T, Iwagami Y, Kobayashi S, Yamanaka C, Sasaki K, Yamada D, Tomimaru Y, Asaoka T, Noda T, Takahashi H, Shimizu J, Doki Y, Eguchi H. Sugimoto T, et al. Among authors: asaoka t. Ann Surg Oncol. 2024 May 9. doi: 10.1245/s10434-024-15349-y. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38722421 No abstract available.
Geriatric prognostic scoring system predicts survival after hepatectomy for elderly patients with liver cancer.
Sakano Y, Noda T, Kobayashi S, Akasaka H, Kato K, Sasaki K, Iwagami Y, Yamada D, Tomimaru Y, Takahashi H, Asaoka T, Shimizu J, Rakugi H, Doki Y, Eguchi H. Sakano Y, et al. Among authors: asaoka t. Ann Gastroenterol Surg. 2023 Dec 19;8(3):498-506. doi: 10.1002/ags3.12762. eCollection 2024 May. Ann Gastroenterol Surg. 2023. PMID: 38707235 Free PMC article.
ASO Visual Abstract: Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
Sugimoto T, Iwagami Y, Kobayashi S, Yamanaka C, Sasaki K, Yamada D, Tomimaru Y, Asaoka T, Noda T, Takahashi H, Shimizu J, Doki Y, Eguchi H. Sugimoto T, et al. Among authors: asaoka t. Ann Surg Oncol. 2024 May 3. doi: 10.1245/s10434-024-15372-z. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38702394 No abstract available.
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).
Yamada D, Kobayashi S, Takahashi H, Iwagami Y, Akita H, Asukai K, Shimizu J, Yamada T, Tanemura M, Yokoyama S, Tsujie M, Asaoka T, Takeda Y, Morimoto O, Tomokuni A, Doki Y, Eguchi H. Yamada D, et al. Among authors: asaoka t. Ann Surg Oncol. 2024 Mar 28. doi: 10.1245/s10434-024-15199-8. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38546797
Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO-HBP-005): Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group.
Kobayashi S, Tomokuni A, Takeda Y, Wada H, Katsura Y, Hashimoto K, Tomimaru Y, Asaoka T, Yamada T, Tsujie M, Noda T, Morita S, Nagano H, Mori M, Doki Y, Eguchi H; Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group. Kobayashi S, et al. Among authors: asaoka t. Hepatol Res. 2024 Jan 27. doi: 10.1111/hepr.14013. Online ahead of print. Hepatol Res. 2024. PMID: 38279693
243 results